Holen Sie sich die Stockscreener-App
507.56
0.04%
0.19
Handel nachbörslich:
507.56
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$507.37
Offen:
$504.34
24-Stunden-Volumen:
234.66K
Relative Volume:
0.65
Marktkapitalisierung:
$11.73B
Einnahmen:
$1.13B
Nettoeinkommen (Verlust:
$-309.44M
KGV:
-39.65
EPS:
-12.8001
Netto-Cashflow:
$-275.41M
1W Leistung:
-0.49%
1M Leistung:
-5.46%
6M Leistung:
+9.22%
1J Leistung:
+36.67%
1-Tages-Spanne:
$494.90
$509.89
1-Wochen-Bereich:
$494.90
$544.49
52-Wochen-Spanne:
$351.31
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
507.56 | 12.39B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo
Madrigal Pharmaceuticals Inc (0JXI) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan - Kalkine Media
Madrigal Pharmaceuticals appoints J&J executive to board - Investing.com
Form 8K Madrigal Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Canada
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors - The Manila Times
Madrigal Pharmaceuticals appoints J&J executive to board By Investing.com - Investing.com India
Madrigal's Board Adds Scientist With More Than 900 Papers - Stock Titan
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Royal Bank of Canada - MarketBeat
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones - Stock Traders Daily
Madrigal at Canaccord Genuity growth conference: Rezdiffra gains pace By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion - webull.com
Madrigal Sets Investor Presentation as MASH Strategy Advances - MyChesCo
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Promising 32.94% Upside in the Biotech Sector - DirectorsTalk Interviews
Assenagon Asset Management S.A. Buys 108,181 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Bank of America Corp DE Sells 226,498 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Madrigal’s Aug. 11 Investor Presentation Will Be Webcast Live - Stock Titan
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Outperform at Wolfe Research - MarketBeat
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 46% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Groupama Asset Managment Buys 4,618 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth - Yahoo Finance
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)? - simplywall.st
Madrigal Pharmaceuticals Shares Slide as Investors Reassess a High Earnings Bar - Quiver Quantitative
Canaccord Genuity Remains a Buy on Madrigal Pharmaceuticals (MDGL) - theglobeandmail.com
Madrigal: Q2 Earnings Snapshot - WKYC
Q2 2026 Madrigal Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Madrigal earnings in focus as Rezdiffra launch accelerates - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Raised to "Strong-Buy" at Wells Fargo & Company - MarketBeat
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MDGL Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring a 24.82% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Paulson & CO. Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. Revenue Breakdown – XETR:YDO1 - TradingView
California Public Employees Retirement System Has $12.14 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Pharmaceuticals (MDGL) to Release Earnings on Thursday - MarketBeat
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553 - Moomoo
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares By Investing.com - Investing.com Australia
UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669 - Moomoo
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):